Our Sponsors + Affiliates
The support of our sponsors and commissions earned when you shop through our affiliates allow us to maintain and update our site, while keeping it free of intrustive ads. Thank you!
Tip: Summarise the methodology in a and then list any notable strengths (e.g., GLP compliance) or limitations (e.g., small sample size, lack of female subjects). 4. Key Findings (Insert exact data from the article; below are placeholders) | Parameter | Control | Low Dose | Mid Dose | High Dose | Comments | |-----------|---------|----------|----------|-----------|----------| | LD₅₀ | — | — | — | 1,200 mg/kg (estimated) | Determined by probit analysis. | | Body‑Weight Change (% over 28 d) | +5.2 % | +3.8 % | –1.1 % | –7.5 % (significant, p < 0.01) | Dose‑dependent decline. | | ALT (U/L) | 32 ± 5 | 35 ± 6 | 48 ± 8* | 73 ± 12** | p < 0.05; p < 0.01 vs. control | | MDA (nmol/mg protein) | 2.1 ± 0.3 | 2.4 ± 0.4 | 3.0 ± 0.5 | 4.6 ± 0.8 * | Indicator of lipid peroxidation. | | Histopathology (Liver) | Normal architecture | Mild vacuolation | Moderate necrosis | Severe necrosis + inflammatory infiltrates | Dose‑related. |